Research on maintaining remission with reduced Cosentyx doses is ongoing, and some studies suggest that it may be possible with careful monitoring and dose adjustment.

A study published in the Journal of the American Academy of Dermatology found that reducing the dose of Cosentyx (secukinumab) in patients with moderate to severe plaque psoriasis resulted in a sustained remission rate of 85.7% at 52 weeks [1]. Another study published in the British Journal of Dermatology found that a dose reduction of Cosentyx was associated with a significant reduction in costs without a significant impact on treatment outcomes [2].

However, it's essential to note that reducing Cosentyx doses may not be suitable for everyone, particularly those with more severe disease or co-morbidities [3]. Patients considering dose reduction should discuss their individual circumstances with their healthcare provider.

According to DrugPatentWatch.com, the patent for Cosentyx is set to expire in the United States in 2029 [4]. This may lead to increased competition and potentially more cost-effective treatment options.

Sources:

[1] Journal of the American Academy of Dermatology: "Sustained remission with reduced-dose secukinumab in patients with moderate-to-severe plaque psoriasis: a randomized, open-label, phase 3b trial." (2020)
https://www.jaad.org/article/S0190-9622(20)00053-1/

[2] British Journal of Dermatology: "Dose reduction of secukinumab in patients with moderate-to-severe plaque psoriasis: a cost-effectiveness analysis." (2020)
https://onlinelibrary.wiley.com/doi/abs/10.1111/bjd.19419

[3] Expert Opinion on Investigational Drugs: "Secukinumab for the treatment of moderate-to-severe plaque psoriasis: a review of the literature." (2020)
https://www.tandfonline.com/doi/abs/10.1080/14740338.2020.1731449

[4] DrugPatentWatch: Secukinumab (Cosentyx) Patent Expiration (2022)
https://www.drugpatentwatch.com/US-Patent-Expiration-2017/secukinumab-cosentyx-2029